Cristina Rondinone
Founder & Chief Executive Officer Pep2Tango Therapeutics
Founder, CEO, Senior executive and leader with more than 25 years experience in the bio pharmaceutical industry with a record of successfully leading teams for the discovery and development of numerous medicines. Founder, CEO Pep2Tango Therapeutics, Council Member TECNALIA, Former Member of the Board of Directors at Axcella (AXLA) and Senior Advisor. Former President of Cellarity and Former Senior VicePresident of AstraZeneca (Medimmune), Head Cardiovascular, Metabolic and Renal Diseases. Set the strategy for the company/area. Built the portfolio of programs and productive teams in different therapeutic areas. Progressed many molecules (more than 10) from target identification to phase3 clinical trials. Built start up. Published more than 80 scientific publications and 4 patents. Inducted as a Member of the Royal Academy of Pharmacy and Biochemistry, Spain.
Seminars
- Compare methods for measuring fat mass, lean mass, visceral and subcutaneous adipose tissue, bone and broader metabolic changes
- Determine which measurements can be aligned from preclinical models through clinical trials to support meaningful comparison
- Establish what evidence would be needed to demonstrate that any body-composition benefit is specific to a molecule, mechanism or receptor profile
